AVL-292CAS号： 1202757-89-8分子式： C22H22FN5O3分子量： 423.44描述纯度储存/保存方法别名外观可溶性/溶解性靶点In vitro(体外研究)In vivo(体内研究)
| 产品描述 | |
| 描述 |
AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed. |
| 纯度 |
>98%
|
| 储存/保存方法 |
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
|
| 基本信息 | |
| 别名 |
CC-292; AVL292; AVL-292; AVL 292;Spebrutinib
|
| 外观 |
Powder
|
| 可溶性/溶解性 |
DMSO 85 mg/mL (200.73 mM)
|
| 生物活性 | |
| 靶点 |
BTK
|
| In vitro(体外研究) |
AVL-292 exhibits dose-dependent inhibition of Btk with EC50 of 8 nM and downstream BCR signaling components in Ramos cells. AVL-292, by inhibiting BTK activities, further inhibits B cell proliferation with EC50 of 3 nM.
|
| In vivo(体内研究) |
In a collagen-induced arthritis mouse model, AVL-292 (3- 30 mg/kg, p.o.) dose-dependently inhibits the clinical signs of inflammatory disease, including reduction in joint and paw swelling and visible redness of the affected paws.
|
分子结构图
